Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization

Trial Profile

Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery restenosis; Myocardial infarction; Stroke
  • Focus Therapeutic Use
  • Acronyms EXCEL
  • Sponsors Abbott Laboratories

Most Recent Events

  • 22 Dec 2020 Results published in the American Journal of Cardiology
  • 06 Oct 2020 Results published in the Journal of the American College of Cardiology
  • 22 Apr 2020 Results assessing the association between smoking status and clinical outcomes among patients undergoing left main coronary artery (LM) revascularization by contemporary PCI or coronary artery bypass grafting (CABG) published in the American Journal of Cardiology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top